These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25542883)

  • 1. Suppression of the immunologic response to peanut during immunotherapy is often transient.
    Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
    J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.
    Thyagarajan A; Jones SM; Calatroni A; Pons L; Kulis M; Woo CS; Kamalakannan M; Vickery BP; Scurlock AM; Wesley Burks A; Shreffler WG
    Clin Exp Allergy; 2012 Aug; 42(8):1197-205. PubMed ID: 22805467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
    J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
    J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.
    Kulis M; Yue X; Guo R; Zhang H; Orgel K; Ye P; Li Q; Liu Y; Kim E; Burks AW; Vickery BP
    Clin Exp Allergy; 2019 Feb; 49(2):180-189. PubMed ID: 30126028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
    Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
    J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.
    Tsai M; Mukai K; Chinthrajah RS; Nadeau KC; Galli SJ
    J Allergy Clin Immunol; 2020 Mar; 145(3):885-896.e6. PubMed ID: 31805311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
    Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and immune regulation with peanut oral immunotherapy.
    Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW
    J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
    Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
    J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy.
    Wisniewski JA; Commins SP; Agrawal R; Hulse KE; Yu MD; Cronin J; Heymann PW; Pomes A; Platts-Mills TA; Workman L; Woodfolk JA
    Clin Exp Allergy; 2015 Jul; 45(7):1201-13. PubMed ID: 25823600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
    Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials.
    Sun J; Hui X; Ying W; Liu D; Wang X
    Allergy Asthma Proc; 2014; 35(2):171-7. PubMed ID: 24717795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.
    Fleischer DM; Burks AW; Vickery BP; Scurlock AM; Wood RA; Jones SM; Sicherer SH; Liu AH; Stablein D; Henning AK; Mayer L; Lindblad R; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2013 Jan; 131(1):119-27.e1-7. PubMed ID: 23265698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on peanut allergy: Prevention and immunotherapy.
    Cook QS; Kim EH
    Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP; Scurlock AM; Kulis M; Steele PH; Kamilaris J; Berglund JP; Burk C; Hiegel A; Carlisle S; Christie L; Perry TT; Pesek RD; Sheikh S; Virkud Y; Smith PB; Shamji MH; Durham SR; Jones SM; Burks AW
    J Allergy Clin Immunol; 2014 Feb; 133(2):468-75. PubMed ID: 24361082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
    J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.
    Kulis MD; Smeekens JM; Burk C; Yue X; Guo R; Orgel KA; Ye P; Herlihy L; Hamilton D; Li Q; Keet C; Shreffler W; Vickery BP; Burks AW; Kim EH
    J Allergy Clin Immunol; 2022 Nov; 150(5):1144-1153. PubMed ID: 35716952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
    Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.